.jpg)
In a report released today, Jason McCarthy from Maxim Group initiated coverage with a Buy rating on VolitionRX (NYSE: VNRX) and a price target of $6. The company’s shares closed yesterday at $2.07, close to its 52-week low of $1.85.
McCarthy said:
“Nucleosome Quantification (Nu.Q) CRC tests are simple, easy to use blood tests that require only a single drop of blood to detect or rule-out CRC.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 4.5% and a 43.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
VolitionRX has an analyst consensus of Moderate Buy, with a price target consensus of $8.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4 and a one-year low of $1.85. Currently, VolitionRX has an average volume of 139.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VolitionRX Ltd. engages in the development of blood-based cancer tests. Its product Nu.Q is a colorectal cancer screening triage test. The company was founded on August 5, 2010 and is headquartered in Singapore.
